Bodal Chemicals Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. - The company is focused on executing existing projects like the Saykha greenfield project and expanding capacities. - They have put some smaller projects on hold to manage capex prudently amid rising steel and cement prices. - Ankit Patel mentioned not wanting to over-leverage and being cautious about project cost overruns. - The strategy includes growing organically via capacity ramp-ups, technology upgrades, and some targeted smaller expansions rather than aggressive acquisitions or new fundraising. - Thus, based on the call, no immediate plans for raising funds via debt or equity were indicated.

- The Saykha greenfield project for benzene derivatives and sulphuric acid is ongoing, with trial runs expected in Q2 FY '24 (benzene derivatives) and Q4 FY '24 (sulphuric acid). - Some small projects with capex around INR 40 crores are put on hold; to be compensated by investments in better technology for PNCB, ONCB, and sulphuric acid. - Revised project cost for Saykha may increase from INR 400 crores to INR 500+ crores, mainly due to steel and shipment price increases. - Certain benzene downstream derivative projects like MPDSA, PNA, 2,4-DNCB are on hold, pending outlook evaluation. - Focus is on integrated product chains for cost efficiency and higher margins in pharma and agrochemical segments. - No aggressive acquisitions currently; growth planned through greenfield expansions and vertical/horizontal integrations, especially in Chlor Alkali, benzene derivatives, and sulphuric acid. - Several sulfuric acid projects under consideration for forward integration in the next phase.

- Bodal Chemicals aims to double dyestuff volumes in the next 2-3 years, particularly leveraging growth in Turkey and surrounding countries. - The company plans to diversify from core Dyestuff and Dye Intermediate business towards specialty chemicals like benzene derivatives, which have higher margins (18-25% EBITDA). - Chlor Alkali business is expected to ramp up capacity utilization to 90% by January 2023, supporting revenue growth. - Saykha greenfield project for benzene derivatives is expected to start trial runs in Q2 FY '24, followed by sulphuric acid trials by Q4 FY '24. - Bodal targets INR 400+ crore turnover from Chlor Alkali and INR 500+ crore from benzene derivatives and sulphuric acid combined once projects stabilize. - Overall, company aims for a blended EBITDA margin increase to approximately 14-15% with new integrated product chains and improved cost structures. - Expansion focuses on reducing dependence on volatile dye intermediate business, bringing it down to 30-40% of total revenue.

- Margins are expected to improve from current 8-12% to around 12-15% in the next 1.5 years as new Greenfield projects (benzene derivatives, sulphuric acid) ramp up to 70-80% utilization. - Addition of Chlor Alkali business and integration is driving growth, targeting over INR 1,000 crores turnover from Chlor Alkali and Greenfield projects with higher margin (18-20%) businesses. - Consolidated EBITDA margins are anticipated to blend to around 14-15%, reflecting higher-margin specialty chemical segments. - Existing core business is steady, but diversification into high entry barrier businesses like Chlor Alkali, benzene derivatives, and sulphuric acid expected to reduce volatility and enhance profits. - Operational efficiencies from technology upgrades (e.g., Rajpura Chlor Alkali) will lower costs and improve margins. - Subsidiary performance improving, notably in Turkey (Sener Boya), aiding earnings growth. - Overall, management aims for consistent margin expansion and revenue growth through capacity ramp-up and new product integration over the next 2-3 years.

The provided transcript and pages from the Bodal Chemicals Limited Q2 FY '23 Earnings Conference Call do not explicitly mention details about the current or expected order book or pending orders. The discussion focuses primarily on business segments, technology upgrades, project updates, financial performance, market dynamics, and strategic initiatives. Therefore, no specific information regarding the current or expected order book or pending orders is available in the given document.